EA201190115A1 - Лечение расстройств, опосредованных нейротрофическим фактором - Google Patents
Лечение расстройств, опосредованных нейротрофическим факторомInfo
- Publication number
- EA201190115A1 EA201190115A1 EA201190115A EA201190115A EA201190115A1 EA 201190115 A1 EA201190115 A1 EA 201190115A1 EA 201190115 A EA201190115 A EA 201190115A EA 201190115 A EA201190115 A EA 201190115A EA 201190115 A1 EA201190115 A1 EA 201190115A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- furostane
- mmp
- muscles
- eyes
- bone
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 6
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract 6
- 239000003900 neurotrophic factor Substances 0.000 title abstract 6
- 230000001404 mediated effect Effects 0.000 title abstract 2
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000001508 eye Anatomy 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 abstract 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 abstract 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 abstract 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 1
- HMMCOAQTWLRBMU-WANIKOBHSA-N O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 HMMCOAQTWLRBMU-WANIKOBHSA-N 0.000 abstract 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- CTYOUOHIEXEYAW-MEVSNGMESA-N furostane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H]3O[C@H](CCC(C)C)[C@@H](C)[C@@H]3[C@@]1(C)CC2 CTYOUOHIEXEYAW-MEVSNGMESA-N 0.000 abstract 1
- FRPYMMBAAIXFOI-UHFFFAOYSA-N furostane Natural products CC(CCC1(O)OC2CC3C4CCC5CC(OC6OC(C)C(O)C(O)C6OC7OC(C)C(O)C(O)C7O)C(O)CC5(C)C4CCC3(C)C2C1C)COC8OC(CO)C(O)C(O)C8O FRPYMMBAAIXFOI-UHFFFAOYSA-N 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000003284 homeostatic effect Effects 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
- 238000001543 one-way ANOVA Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 229950002323 smilagenin Drugs 0.000 abstract 1
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 abstract 1
- 238000007619 statistical method Methods 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14708409P | 2009-01-24 | 2009-01-24 | |
| CN2009070319 | 2009-01-24 | ||
| PCT/GB2010/050098 WO2010084356A1 (en) | 2009-01-24 | 2010-01-22 | Treatment of neurotrophic factor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201190115A1 true EA201190115A1 (ru) | 2012-02-28 |
Family
ID=41800830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201190115A EA201190115A1 (ru) | 2009-01-24 | 2010-01-22 | Лечение расстройств, опосредованных нейротрофическим фактором |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120034193A1 (enExample) |
| EP (1) | EP2389182A1 (enExample) |
| JP (1) | JP2012515754A (enExample) |
| KR (1) | KR20110115589A (enExample) |
| AU (1) | AU2010207597A1 (enExample) |
| BR (1) | BRPI1005372A2 (enExample) |
| CA (1) | CA2750510A1 (enExample) |
| EA (1) | EA201190115A1 (enExample) |
| IL (1) | IL214242A0 (enExample) |
| MX (1) | MX2011007842A (enExample) |
| SG (1) | SG173094A1 (enExample) |
| WO (1) | WO2010084356A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130043197A (ko) * | 2010-07-20 | 2013-04-29 | 파이토팜 피엘씨 | 엘-도파, 도파민 효능제 및/또는 도파민 증강제 유도된 장애의 치료 |
| US8708906B1 (en) * | 2011-09-07 | 2014-04-29 | Allen J. Orehek | Method for the prevention of dementia and Alzheimer's disease |
| RU2501562C1 (ru) * | 2012-11-01 | 2013-12-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук ФГБУ "НИИ фармакологии" СО РАМН | Средство, обладающее церебропротекторной активностью |
| WO2014100433A1 (en) * | 2012-12-19 | 2014-06-26 | Brown University | Methods for treatment of microcephaly associated autism disorders |
| WO2017218697A1 (en) * | 2016-06-17 | 2017-12-21 | The Trustees Columbia University In The City Of New York | Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| CA3036688A1 (en) * | 2016-09-12 | 2018-03-15 | University Of South Florida | Neuroregeneration improved by ketone |
| EP4245368A3 (en) | 2016-12-21 | 2024-01-03 | Universitäts-kinderspital Beider Basel | Migraine prevention and treatment |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US9925164B1 (en) | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| BR102017016550A2 (pt) | 2017-08-01 | 2019-03-19 | Lisis Rojo Gomes | Uso de glicosídeos esteroidais, formulações farmacêuticas, uso de extratos da planta furcraea foetida, processo de obtenção de extratos da planta furcraea foetida e método de tratamento de distúrbios da pele |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US11617772B2 (en) | 2018-09-11 | 2023-04-04 | Direct Digital Llc | Nutritional supplements and therapeutic compositions comprising probiotics |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| KR102779301B1 (ko) | 2021-12-13 | 2025-03-13 | 한국한의약진흥원 | 근위축 개선, 예방 또는 치료용 조성물 |
| CN115282156A (zh) * | 2022-09-05 | 2022-11-04 | 广东海洋大学 | 知母皂苷元在制备防治帕金森病的药物中的应用 |
| KR102553713B1 (ko) * | 2022-11-18 | 2023-07-10 | 고덕상 | 미네랄 촉매제를 이용한 양식어류사료 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0102416A1 (en) | 1982-08-23 | 1984-03-14 | Nutrisearch Company | Blends of egg albumen and whey protein of improved gel strength |
| JP4740426B2 (ja) | 1997-03-17 | 2011-08-03 | ビーティージー・インターナショナル・リミテッド | 治療用組成物 |
| CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| DK1066042T3 (da) | 1998-03-26 | 2006-12-18 | Phytopharm Plc | Steroidale saponiner til behandling af Alzheimers sygdom |
| EP1123094B1 (en) | 1998-09-15 | 2007-04-11 | Btg International Limited | Therapeutic compositions (ii) |
| GB9923078D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US7795218B2 (en) * | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
| DE10162058A1 (de) * | 2001-12-17 | 2003-07-24 | Cospharcon Gmbh | Gefäßaktive, juckreiz- und entzündungslindernde Zubereitung zur Minimierung der unangenehmen Begleiterscheinungen hämorrhoidaler Affekte und Ekzeme im Analbereich sowie als unterstützende Maßnahme zur Intertrigo- und Dekubitus-Prophylaxe bei entsprechend disponierten Personen. |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| MXPA04009321A (es) * | 2002-03-27 | 2005-01-25 | Phytopharm Plc | Metodos y usos terapeuticos de sapogeninas y sus derivados. |
| US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
| US20050100531A1 (en) * | 2002-06-13 | 2005-05-12 | John Bienenstock | Probiotic therapies |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| PT1706121E (pt) * | 2004-01-12 | 2008-12-04 | Solvay Pharm Bv | Inibidores de endopeptidase neutra (nep) e endopeptidase humana solúvel (hsep) para profilaxia e tratamento de distúrbios neurodegenerativos |
| NZ548926A (en) * | 2004-02-09 | 2009-07-31 | Regenion Gmbh | Inhibitors of TGF-R signaling for treatment of CNS disorders |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| CN1692914B (zh) | 2004-04-29 | 2010-05-26 | 中国人民解放军军事医学科学院放射医学研究所 | 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途 |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
-
2010
- 2010-01-22 EA EA201190115A patent/EA201190115A1/ru unknown
- 2010-01-22 US US13/138,251 patent/US20120034193A1/en not_active Abandoned
- 2010-01-22 WO PCT/GB2010/050098 patent/WO2010084356A1/en not_active Ceased
- 2010-01-22 JP JP2011546964A patent/JP2012515754A/ja active Pending
- 2010-01-22 EP EP10702341A patent/EP2389182A1/en not_active Withdrawn
- 2010-01-22 SG SG2011052867A patent/SG173094A1/en unknown
- 2010-01-22 MX MX2011007842A patent/MX2011007842A/es not_active Application Discontinuation
- 2010-01-22 CA CA2750510A patent/CA2750510A1/en not_active Abandoned
- 2010-01-22 AU AU2010207597A patent/AU2010207597A1/en not_active Abandoned
- 2010-01-22 KR KR1020117019497A patent/KR20110115589A/ko not_active Ceased
- 2010-01-22 BR BRPI1005372A patent/BRPI1005372A2/pt not_active IP Right Cessation
-
2011
- 2011-07-21 IL IL214242A patent/IL214242A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2389182A1 (en) | 2011-11-30 |
| US20120034193A1 (en) | 2012-02-09 |
| CA2750510A1 (en) | 2010-07-29 |
| MX2011007842A (es) | 2012-01-12 |
| IL214242A0 (en) | 2011-09-27 |
| SG173094A1 (en) | 2011-08-29 |
| JP2012515754A (ja) | 2012-07-12 |
| KR20110115589A (ko) | 2011-10-21 |
| AU2010207597A1 (en) | 2011-08-18 |
| BRPI1005372A2 (pt) | 2018-03-06 |
| WO2010084356A1 (en) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201190115A1 (ru) | Лечение расстройств, опосредованных нейротрофическим фактором | |
| Shadmehr et al. | Hamstring flexibility in young women following passive stretch and muscle energy technique | |
| Calvey et al. | Short-term electrical stimulation to promote nerve repair and functional recovery in a rat model | |
| Sajer et al. | Myokines in home-based functional electrical stimulation-induced recovery of skeletal muscle in elderly and permanent denervation | |
| Caldeira et al. | Extracellular matrix constitution and function for tissue regeneration and repair | |
| CN104055723B (zh) | 一种天然免洗的睡眠面膜 | |
| Hallemans et al. | Playing music may improve the gait pattern in patients with bilateral caloric areflexia wearing a cochlear implant: results from a pilot study | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| DE602007005041D1 (de) | Verfahren zur Behandlung von Entzündungserkrankungen mit Maracujaextrakten | |
| Deng et al. | Radix angelica sinensis promotes synaptic plasticity during cognitive recovery in chronically stressed rats | |
| US10596204B2 (en) | Use of propolis for combating pathological conditions associated with obesity | |
| Zhang et al. | Effects of neonatal inflammation on descending modulation from the rostroventromedial medulla | |
| Peng et al. | Effects of neonatal hypoxic-ischemic episodes on late seizure outcomes in C57 black mice | |
| ES2635421T3 (es) | Composiciones farmacéuticas que comprenden (S)-(+)-7-(1H-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para tratar enfermedades y trastornos cutáneos | |
| Nam et al. | Effects of galvanic vestibular stimulation on vestibular compensation in unilaterally labyrinthectomized mice | |
| IT201900002109A1 (it) | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale | |
| Chan et al. | Effects of Spirulina on GABA-Receptor Gene Expression in Salicylate-Induced Tinnitus | |
| WO2024173520A3 (en) | Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereof, and methods of use | |
| MX2023005663A (es) | Tratamientos respiratorios. | |
| CN105770013A (zh) | 一种用于治疗颞下颌关节紊乱的中药及其制备方法 | |
| RU2751823C1 (ru) | Способ физиотерапии аносмии после коронавирусной инфекции | |
| Park et al. | Effects of swiss ball exercise on functional activity and pain in shoulder dislocation patients | |
| RU2403072C2 (ru) | Метод вольдемара рагеля - способ электротерапии человека | |
| Sawant et al. | Effect of task-specific training in frozen shoulder | |
| Lopes et al. | Exercise and Trasncranial Direct Current Stimulation (tDCS) change the nociceptive response and brain-derived neurotrophic factor (BDNF) levels in the cerebral cortex and spinal cord in a model of chronic pain: short-term effects |